Answers are grounded in this paper and cite their sources.
Research finds tumor growth is linked to CD83 on dendritic cells, implying that targeting this checkpoint may enhance cancer treatment.
Description CCR7+dendritic cells (DC) are associated with favorable responses to immune checkpoint blockade. They have been found in intratumoral niches in proximity of CD4+ and CD8+ T cells. How CCR7+DC control intratumoral T cell infiltration, restrain intratumoral responses, and influence cancer outcomes is not fully understood. Here we show that, by limiting the expression of activation marker CD83 on CCR7+DC, we could increase the intratumoral amount of CD8 T cells and control cancer in mice. Reduction of membrane-bound CD83 determines a pro-inflammatory CCR7+DC state that correlates with the expansion of intermediate effector-like CD8 and tumor control. Additionally, CD83 levels on CCR7+DC negatively correlate with intratumoral CD8 T cell infiltration in distinct human cancers. These observations reveal that CD83 on CCR7+DC is a cellular and molecular tumor checkpoint that limits CD8 T cell immune-responses and has the potential to be exploited in cancer treatment. Funding Sources Cancer Prevention and Research Institute of Texas (CPRIT; RR210017) Robert J. Kleberg, Jr. and Helen C.
No takes yet. Share an insight, caveat, or question.
Pilato et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: